Please see below for a list of search results.
Contact details for the transplant teams across the country can be found here.
NHS Blood and Transplant (NHSBT)
Procurement is defined by the EU Tissue and Cells Directives as a process by which tissues or cells are made available. This includes the donor selection procedure as well as the physical act of removing tissue and / or cells intended for patient treatment (human application).
A licence for the removal of relevant material from a deceased person authorises an establishment to remove material for purposes such as research. It does not authorise the procurement of tissues and / or cells for human application.
It is a requirement that the DI must have:
It is the responsibility of the Designated Individual of the licensed establishment to communicate information to third parties, including regulatory alerts and other relevant communications from the HTA regarding serious adverse events and reactions (SAEARs).
The Designated Individual (DI) of the licensed establishment is responsible for assessment and documentation of the adverse incident occurring under the licence, and reporting of any serious adverse event or reaction to the HTA and any other affected establishments.
The DI should:
Our intention in extending the publication scheme is to be more transparent about the regulatory action we take. This is in the public interest. We want to maintain and enhance the confidence of the public, on whose behalf we regulate. An establishment that is inspected has the benefit of the...
Yes. The HTA and other health regulators are required to comply with the MacRory report (“Regulatory Justice: Making Sanctions Effective” – Professor Richard MacRory).